Introduction
Intravenous immunoglobulin (IVIG) is a therapeutic product derived from the pooled plasma of thousands of people. It is used to treat immune-deficient patients who have reduced antibody levels. IVIG has also been tried as a treatment for Alzheimer's disease (AD) (Devi et al., 2008; Fillit et al., 2009; Relkin et al., 2009) , the rationale being that it contains antibodies against the toxic protein β-amyloid (Aβ), the main component of amyloid plaques, which are a hallmark feature of AD. IVIG is thus thought to augment the presumed relatively low level of the patients' Aβ antibodies, thereby enhancing Aβ clearance. However, although treatment led to some encouraging preliminary effects on cognitive function (Devi et al., 2008; Relkin et al., 2009) , the usage of monoclonal anti-Aβ antibodies for treatment has not yet done so. One explanation is that the treatment was given at too late a stage in the disease (therefore to investigate this, new trials are being set up which will initiate treatment at a much earlier stage). Alternatively, in the positive preliminary studies, IVIG might have affected some factor other than Aβ, perhaps through its antiviral properties. IVIG contains large amounts of neutralising antibodies to many microbes and so in AD patients it might have inhibited the action of an infectious agent.
Herpes simplex virus type 1 (HSV1), a microbe against which IVIG is known to have antiviral action (Erlich and Mills, 1986; Kohl and Loo, 1986; Masci et al., 1995) , has been implicated as a cause of AD. The first relevant finding was our discovery that HSV1 DNA is present in a high proportion of AD patients and aged normals (Jamieson et al., 1991 (Jamieson et al., , 1992 and that when in brain of APOE-ε4 carriers it confers a strong risk for AD (Itzhaki et al., 1997; Lin et al., 1998) . Later, we detected intrathecal antibodies to HSV in aged normals and AD patients (Wozniak et al., 2005) , confirming HSV1 presence in brain and indicating that the virus had been actively replicating -and hence likely causing damage. We then found that HSV1-infection of cultured neural cells causes a large increase in Aβ, and that Aβ deposition occurs in brains of HSV1-infected mice (Wozniak et al., 2007) ; also, in HSV1-infected neural cell cultures, abnormally phosphorylated tau (P-tau), the main component of neurofibrillary tangles, is formed (Wozniak et al., 2009a) . Recent data by others support these results in showing similar effects of HSV1 on Aβ and P-tau (see (Alvarez et al., 2012) and references within (Wozniak et al., 2011)) . A further major discovery was that in AD brains, HSV1 DNA localises very specifically to amyloid plaques (Wozniak et al., 2009b) . The latter result, together with the fact that HSV1 causes Aβ production, suggests that HSV1 is a major factor in the formation of toxic Aβ products and amyloid plaques.
These data point to the use of antiviral agents to stop the progression of AD. The main antiviral agent used to combat HSV1 is acyclovir (ACV); however, antivirals such as ACV that target HSV1 DNA replication might be successful only if Aβ and P-tau accumulations depend on viral DNA replication, prompting us to investigate ACV effects on Aβ and P-tau in HSV1-infected cells. We found that P-tau accumulation does depend on HSV1 DNA replication whereas Aβ accumulation does not, but treatment of HSV1-infected cell cultures with ACV greatly reduces both products (Wozniak et al., 2011) , P-tau through the decreased replication and Aβ through the decreased production of new viruses and hence decreased viral spread. However, ACV did not reduce Aβ to control levels, suggesting that antivirals which act prior to viral DNA replication might be preferable for treating AD. IVIG is a possibility as it can neutralise extracellular virus and also help (in conjunction with lymphocytes) to destroy cells acutely infected with HSV1 (Kohl and Loo, 1986 ) -a useful feature as the virus can be transferred from cell to cell without the release of extracellular virus. In the present preliminary study we therefore aimed to find if IVIG reduces the production of Aβ and of P-tau, to compare any such reductions with those produced by ACV, and to find the combined effect of the two agents, using infected cell cultures.
Methods

Viruses, cells and antiviral agents
We used HSV1 strain SC16 prepared as previously described (Dobson et al., 2006) . African Green Monkey kidney (Vero) cells were cultured as previously described (Wozniak et al., 2011) . ACV was purchased from Sigma-Aldrich and IVIG (Privigen) was provided by CSL Behring.
Vero cells were cultured into wells of 24-well plates at 80% confluency and left overnight to settle. HSV1 infection was carried out either at a dose of 20 plaque-forming units (pfu/cell), incubating the cells for 7 h, or at a dose of 0.01 pfu/cell, incubating for 23 h. ACV or Privigen, or in the case of the low dose, long incubation experiments, ACV and Privigen together, were added concurrently with the virus suspension. After the incubation, the cells were fixed in PBS containing 4% formaldehyde and 10% acetic acid.
Immunocytochemistry
Cells were washed twice in Tris-buffered saline (TBS) for 5 min and then twice in TBS containing 0.025% Triton X-100 (TBS-Tx) (each wash lasting 5 min), before being blocked for 1 h at room temperature in TBS containing 10% goat serum. After two five-minute washes in TBS-Tx, primary antibody was applied. Slides were incubated overnight at 4°C, washed in TBS-Tx and biotinylated secondary antibody was added for 1 h. Subsequently, the slides were washed in TBS-Tx and then treated with an extravidin-alkaline phosphatase conjugate for 30 min before being washed in TBS. Substrate (BCIP/NBT) was then added until sufficient staining had developed. The primary and secondary antibodies have been described previously (Wozniak et al., 2011) .
Quantification of results
We quantified the ICC staining using the image analysis software Image J, which we previously validated for HSV1 using standard virological methods -HSV1 ELISA and plaque reduction assays (Wozniak et al., 2011) . For each antibody we analysed three fields of view, measuring the total staining in the field. With Aβ, presence of Privigen resulted in background staining; to compensate for the latter, values obtained for mock-infected cells were subtracted.
To examine the effects on viral spread, we used low HSV1 doses for relatively long duration; this resulted in the formation of clusters of cells of size up to a few hundred cells per area. To assess the effect of ACV and Privigen on the numbers of cluster, numbers were counted in four fields of view, and the average number was determined. Student's T-test was used to determine statistically significant differences between the quantitative ICC values. Student's T-test was used also to determine difference in the number of clusters. In each case, Fig. 1 . The effect of Privigen (and acyclovir) on HSV1 proteins, β-amyloid and abnormal tau phosphorylation (high HSV1 dose, short duration). Vero cells were infected with HSV1 SC16 (20 pfu/cell) for 7 h, which allowed only 1 cycle of viral replication to occur. Cells were treated either with 0.4 mg/ml acyclovir (ACV), or with 0.4 mg/ml, 5 mg/ml or 10 mg/ml Privigen, or were untreated; the antivirals were present throughout infection. After fixation the cells were tested for HSV1 proteins, β-amyloid accumulation and abnormal tau phosphorylation (AT100) using immunocytochemistry. Scale bars: 50 μm.
values for each antiviral treatment were compared with values for no antiviral treatment.
Results
Effects of Privigen during infection level and duration sufficient for 1 cycle of HSV1 replication in all cells
Initial experiments were carried out using a sufficiently high dose of HSV1 to ensure that every cell was infected on initial exposure to the virus; this enabled the expected preventive action of Privigen on virus entry to be detectable. We examined the effects of Privigen at 0.4, 5 and 10 mg/ml, but ACV only at 0.4 mg/ml (in aqueous solutions ACV is not soluble at 5 and 10 mg/ml). Fig. 1 shows that Privigen greatly reduced levels of HSV1 proteins, Aβ and P-tau. At 5 and 10 mg/ml there was a large reduction in HSV1, P-tau and Aβ, suggesting that Privigen greatly reduced viral entry and hence production of Aβ and P-tau. There was a modest effect with Privigen at 0.4 mg/ml. ACV had only a modest effect on levels of all proteins, presumably because its concentration was insufficient to reduce viral DNA replication adequately. Quantification shows that at 0.4 mg/ml, ACV reduced HSV1 staining by 52% (compared with the values obtained for HSV1-infected, no antiviral), and Privigen, at the same w/v concentration, reduced the staining by 58% (Fig. 2) . For Aβ, ACV reduced staining by only 10% whereas Privigen, at the same w/v concentration, reduced the staining by 64%. For P-tau, ACV reduced staining by 20% whereas Privigen, at the same w/v concentration, reduced the staining by 64%. Further, higher concentrations of Privigen were much more effective, reducing HSV1, Aβ and P-tau stainings to very low levels.
Effects of Privigen during infection level and duration appropriate for cell-to-cell spread of HSV1
We investigated the effect of Privigen on the spread of HSV1 using a low dose of HSV1 for a long duration. This allowed viral cell-to-cell spread and caused clustering of infected cells, which were clearly visible when stained by immunocytochemistry for HSV1 proteins, Aβ and P-tau (Fig. 3) . All three types of staining showed that treatment with ACV at 0.4 mg/ml reduced the size of clusters considerably (resulting in most cases to a single cell), but not their number. Privigen treatment did reduce cluster number -to zero at 5 mg/ml and 10 mg/ml, and reduced cluster size slightly at 0.4 mg/ml (Fig. 3) .
Effects of Privigen and ACV together during cell-to-cell spread of HSV1
The combination of ACV and Privigen had little effect on the cluster size compared with ACV alone (Fig. 4) . Quantification of the results revealed that at 0.4 mg/ml, ACV reduced the staining of clusters for HSV1, Aβ and P-tau by 93%, 71% and 84%, respectively (Fig. 5A) . Privigen reduced staining by 90%, 10% and 26%, and the combination by 97%, 68% and 84%, respectively. Analysis of the numbers of clusters (based on HSV1 staining) (Fig. 5B) revealed that ACV had no effect on the actual number of clusters but Privigen reduced their number as did the combination. In the case of Aβ and P-tau, ACV reduced the number of clusters but the effect was greater with Privigen and with the combination. These results show that the combination of Privigen and ACV reduces both the number of clusters and the size of the clusters.
Discussion
Our first main finding is that in HSV1-infected Vero cells, Privigen causes statistically significant reductions, particularly at higher concentrations, in levels of Aβ and P-tau, as well as in HSV1 proteins. This probably results from Privigen preventing viral entry into cells; thus, few viruses would enter the cells and few cells would be stained. ACV does not affect virus entry, so it would not affect numbers of infected cells, but by inhibiting virus replication it would reduce subsequent spread -accounting for the small cluster sizes and low staining.
Our second finding is that Privigen and ACV together act synergistically, causing statistically significant reductions in these levels, presumably resulting from the combination of prevention of viral entry and inhibition of DNA replication of any virus that has evaded the prevention. These data suggest that Privigen would be a suitable antiviral agent for treating AD, and that its action would be even more effective if used in combination with ACV.
IVIG is known to act against a number of infectious diseases. Its mechanisms of action are believed to include neutralisation of pathogens and of their cell receptors (Bayry et al., 2004) . It has been used successfully to treat HSV1 diseases in animals and humans. In murine Fig. 2 . The effect of Privigen (and acyclovir) on levels of HSV1 proteins, β-amyloid and abnormal tau phosphorylation. Vero cells were infected with HSV1 SC16 (20 pfu/cell) for 7 h, which allowed only 1 cycle of viral replication to occur. Cells were treated either with 0.4 mg/ml acyclovir (ACV), or with 0.4 mg/ml, 5 mg/ml or 10 mg/ml Privigen, or were untreated; the antivirals were present throughout infection. After fixation the cells were tested for (A) HSV1 proteins, (B) β-amyloid (Aβ) accumulation and (C) abnormal tau phosphorylation (AT100) using immunocytochemistry, and the amount of staining was quantified using Image J. Values are expressed as a percentage of staining produced when no antiviral was used. p-Values indicate statistical significance (using Student's T-test) of data for each antiviral treatment compared with no antiviral treatment. models of the rare but very serious brain disease, herpes simplex encephalitis, IVIG protected the animals against death, and it reduced the number of trigeminal ganglia containing latent HSV1 (Erlich and Mills, 1986) . Further, IVIG-treated genital herpes in humans (caused by HSV1 as well as HSV2) reduced recurrence frequency and duration, and lesion severity more effectively than did ACV, and there was a trend towards IVIG causing a greater reduction in viral load (Masci et al., 1995) (also, most patients preferred the IVIG treatment of one day per month compared to that of ACV twice per day for one week each month.). We have proposed that HSV1 in brain reactivates from latency, as it does in the peripheral nervous system, during events such as stress and peripheral infections, and that it then causes damage which is particularly severe in APOE-ε4 carriers, leading to the development of AD. Therefore if IVIG reduces HSV1 reactivation frequency and duration in the brain as it does in genital herpes, it should be a particularly effective antiviral agent for treating AD.
Interestingly, a small scale retrospective study of AD patients treated with IVIG for a few months found that it was well-tolerated, and that neurocognitive test scores were either stable or else showed trends towards improvement in some aspects (Devi et al., 2008) . A subsequent equally small study of IVIG-treated patients with mild AD showed that anti-Aβ antibodies in serum increased proportionately to IVIG dose, and that mini-mental state scores increased during treatment (Relkin et al., 2009) . A recent retrospective study found that prior treatment with IVIG (at least once during a 3 year period) reduced the risk of developing AD in patients aged 65 years or over, compared with untreated controls, although over 30% of those treated with IVIG had cancer diagnoses, and so their lower risk of AD might have reflected their associated treatments and diagnoses (Fillit et al., 2009) . It is unknown whether or not in these studies there was an IVIG-induced anti-HSV1 action (especially in APOE-ε4 carriers, but unfortunately no data on APOE genotypes were given).
However, an anti-HSV1 action might explain the apparent paradox that monoclonal Aβ antibody treatment was not beneficial (Relkin et al., 2009 ). Our results suggest that at least in some patientsthose with HSV1 in brain and who were APOE-ε4 carriers, the protective effect of IVIG might have been mediated via its inhibitory action on HSV1 and the consequent reduction in Aβ and P-tau. Fig. 4 . Effects of combined acyclovir and Privigen treatment on HSV1 proteins, β-amyloid and abnormal tau phosphorylation. Cells were infected with HSV1 SC16 (0.01 pfu/cell) for 23 h, which allowed cell-to-cell spread of the virus and resulted in clusters of infected cells. Cells were treated with acyclovir (ACV) or Privigen (each at 0.4 mg/ml), the combination (each at 0.4 mg/ml), or were untreated; the antivirals were present throughout infection. After fixation the cells were tested for HSV1 proteins, β-amyloid accumulation and abnormal tau phosphorylation (AT100) using immunocytochemistry. Scale bars: 50 μm. Fig. 5 . The effect of the combination of Privigen and acyclovir on HSV1 proteins, β-amyloid and abnormal tau phosphorylation. Cells were infected with HSV1 SC16 (0.01 pfu/cell) for 23 h, which allowed cell-to-cell spread of the virus and resulted in clusters of infected cells. Cells were treated with 0.4 mg/ml acyclovir (ACV), with 0.4 mg/ml Privigen, or with the combination (each at 0.4 mg/ml) or were untreated; the antivirals were present throughout infection. After fixation the cells were tested for HSV1 proteins, β-amyloid (Aβ) accumulation and abnormal tau phosphorylation (AT100) using immunocytochemistry. The amount of staining within clusters was quantified using Image J (A). Values are expressed as a percentage of staining produced when no antiviral is used. The numbers of clusters stained for HSV1 proteins, Aβ and abnormal tau phosphorylation were determined also (B). p-Values indicate statistical significance (using Student's T-test) of data for each antiviral treatment compared with no antiviral treatment.
